Germany’s Health-Spending Plan Has Consequences as Lilly, Boehringer Scale Back
22 Articles
22 Articles
The large pharmaceutical companies Eli Lilly and Boehringer Ingelheim reduce their investments in Germany. The local market does not apply to the companies ... The post Bad location conditions: Pharmaceutical companies withdraw from Germany appeared first on Apollo News.
Out of displeasure about German health policy, the US company Eli Lilly halves its investments in Alzey. The pharmaceutical company Boehringer Ingelheim also stops the expansion of sites in this country.
The US pharmaceutical company Eli Lilly is returning its planned billion-dollar investment to a new production site in Alzey, Rhineland-Palatinate.
The U.S. pharmaceutical company Lilly halved its planned investment in Rhineland-Palatinate. Boehringer Ingelheim is also cutting back on plans. Both companies also refer to the government's policy as a reason.
With a major reform of the statutory health insurance the Federal Government wants to save costs. Therefore, pharmaceutical companies rethink their investments. Two large companies now have bad news for the location Germany.
US pharmaceuticalist Eli Lilly reduces the investment for the planned production site to a minimum and refers to the Federal Government's savings plans. A German company also stops investments.
Coverage Details
Bias Distribution
- 40% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
